image
Technology - Software - Infrastructure - NASDAQ - US
$ 3.38
-4.52 %
$ 181 M
Market Cap
26.0
P/E
EARNINGS CALL TRANSCRIPT
EARNINGS CALL TRANSCRIPT 2019 - Q1
image
Operator

Welcome to the PaySign, Inc. First Quarter 2019 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded.

This presentation may include forward looking statements to the extent that the information presented in this presentation discusses financial projections, information and expectations about the company's business plans, results of operations, returns on equity, markets, or otherwise make statements about future events.

Such statements are forward looking. Such forward looking statements can be identified by the use of words such as should, may, intend, anticipates, believes, estimates, projects, forecast, expects, plans or proposes.

Although the company believes that the expectations reflected in these forward looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward looking statements.

You are urged to carefully review and consider any cautionary statements and other disclosures including the statements made under the heading risk factors, and elsewhere in our 2018 Form 10K.

Forward looking statements speak only as of the date of the document in which they are contained, and the company does not undertake any duty to update any forward looking statements except as may required by law.

This presentation also includes adjusted EBITDA and non-GAAP financial measure that is not prepared in accordance with nor an alternative to financial measures prepared in accordance with U.S. generally accepted accounting principles, GAAP.

In addition, adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies. It's my pleasure to introduce your host, Mark Newcomer, CEO for PaySign. Please go ahead, sir..

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

Thank you, Kevin. Good afternoon, everyone. On behalf of PaySign, I'd like to welcome you to our first quarter earnings call. I'm Mark Newcomer, Chief Executive Officer at PaySign Incorporated. I will provide a brief overview of some of the highlights for the first quarter, touch on strategy and reinforce our outlook for the remainder of the year.

Following my remarks, I'll turn it over to our Chief Financial Officer, Mark Attinger to take us through the first quarter results following March review we will then field your questions. Some of you may be new to following up our company, briefly the company was founded in 2001.

PaySign is both a vertically integrated processor and a prepaid card program manager we developed customized and innovative payment solutions in support of corporate, consumer and government programs.

To learn more about our history and the services we provide and to review our most recent investor presentation, you may want to visit the investor section of our website at www.paysign.com. Overall, I'm very pleased with our financial results and our continued ability to execute both operationally and technologically.

These are key differentiators for our company that enable us to effectively retain and grow our existing client programs and secure new business. Also, I'm sure that you are all aware of our recent company name and ticker symbol change. Effective April 30, 3PEA International, Inc. became PaySign, Inc.

and our stock began trading under our new NASDAQ ticker symbol PAYS. The new corporate name was chosen to better align the company with our PaySign branded prepaid cards and virtual payment solutions. PaySign better reflects the identity, vision and direction of our company as a prepaid payment solution provider.

Additionally, the PaySign name better enables us to clearly convey the value proposition of our brand in both our commercial and consumer prepaid card offerings. Turning to our very strong first quarter results, in summary revenues were record 7.3 million, an increase of 55% compared to the prior year.

Net income was 1.9 million, up a 111% and adjusted EBITDA was 1.7 million, an increase of 121% year over year. We continue to experience excellent growth in our existing programs, and are now seeing growth from newly added clients in the pharmaceutical industry.

We expect to continue strong growth and have kept our full year guidance of revenues of 38 million to 40 million and adjusted EBITDA of 10 million to 12 million unchanged.

Strategically, as I stated during our previous call, we will continue to broaden and diversify our market focus on our prepaid card programs, and will seek to introduce new products. We continue to prepare for the launch of our PaySign premier card which is expected in Q2.

Just to preempt the question, there is nothing new to report on the M&A front product. As I have shared previously, we continue to pursue acquisition candidates that have long standing reputations, corporate culture of innovation and have demonstrated growth and profitability.

At this time, I'd like to turn it over to Mark to take us through the numbers. .

Mark Attinger

Excellent. Thank you, Mark. So I'll take us through the first quarter top line numbers and provide some variants commentary. I'll then add to Mark's comments pertaining to 2019. Before I begin unless stated otherwise, any reference to 2018 or prior year pertains specifically to the first quarter of 2018.

So revenue for the quarter ended March 31, 2019 was 7.257290 million, an increase of 55.2% compared to 4.676320 million the prior year better than our expectations. This increase in revenue is attributable to continued client growth in the non-pharma industries and growth in new pharm clients on-boarded in the second half of 2018 and early 2019.

Gross profit improved to 68.3% to 3.8 million or 52% of revenues, compared to 2.2 million and 48% of revenues in 2018. The 405 basis point improvement resulted primarily from a higher gross margin percent contributed from the mix of new pharma business. Total operating expenses were 3.0 million compared to 1.8 million.

The increase consists primarily of 614,000 and incremental salaries and benefits and 509,000 increase in stock based compensation, both primarily driven by investments in new personnel in the second half of 2018.

However, as expected, we are beginning to see improved operating leverage as SG&A increased just 113,000 or 4.4%, compared to fourth quarter 2018. As you may recall from the earnings call we recently did for year end, we do expect interest income for the full year to be an excess of 400,000 resulting from higher cash balances.

For the first quarter, benefiting from an increase of 19.5 million in consolidated cash, interest income was 119,000 versus just 20,000 in the prior year. Net income was $871, 671, an increase of 111.3% compared to $412,548 the prior year. And both the fully diluted and basic earnings per share were $0.02 compared to $0.01 the prior year.

Non-GAAP adjusted EBITDA was 1.717479 million, an increase of 121.5% compared to $775, 387 the prior year. Furthermore, the adjusted EBITDA margin improved nicely to 23.7% of 708 basis points from just 16.6% in Q1 2018, non-GAAP EPS was $0.04 versus $0.02 the prior year.

We loaded 191 million to the card for the quarter, and that's in dollars, versus 127 million in 2018. Our revenue conversion rate of growth dollar volume loaded on cards for the quarter was 3.79% or 379 bps versus 3.68% or 368 basis points for the prior year.

From a balance sheet perspective consolidated cash increased 61% or 19.5 million to 51.1 million compared to 31.7 million reflected just three months previously at year end.

Working capital, current assets less current liabilities increased to 7.2 million from 6.0 million at year-end due to increased AR from higher client billings and an increase in restricted cash partially offset by a smaller increase in the card funding liability.

Our liquidity as measured by an adjusted current ratio, excluding restricted cash and cardholder funds from both sides of the balance sheet respectively, was 12.0, up from 5.4 at year-end and finally, there remains no debt on the balance sheet.

Looking forward, as Mark mentioned, there are no changes to our guidance at this time as we continue to execute against our operating plan. We expect to see improved gross margins and operating leverage, resulting in higher net and adjusted EBITDA margins. I think that's it for now.

At this time, I'll turn it back over to the moderator Kevin to begin the question and answer session. Thank you. .

Operator

[Operator Instructions]. Our first question today is coming from Austin Moldow from Canaccord Genuity. Your line is now live..

Austin Moldow

I wanted to ask about revenue.

So revenue growth accelerated this quarter from Q4, 2018 I'm wondering if you can give some color on how much the pharm business contributed to that acceleration?.

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

We won't isolate it on a specific quarter, it did contribute close to 15% and we do expect that pharma on a full year basis will probably represent about 20% of our guidance for full year revenue. .

Austin Moldow

I also wanted to ask about expense leverage.

What are the primary areas you see that you will be investing in this year? And where might that maybe margin vary from where you're currently guide into?.

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

Yes, it's good question. So, and we touched on this a little bit on the prior call. We do make investments in software and technology. So both on the fixed asset as well as the intangible asset side, roughly 2.25 million to 2.5 million would be our investments we expect for the year.

So from an operating expense standpoint, you'll of course see that growing at a slower rate than it did last year and therefore representing a smaller percentage of revenues, if you will generating higher EBITDA and net margins..

Austin Moldow

And my last question is on the plasma business. So I think you said your share for plasma market is 33% in 2018.

Any update to that now or where you think it might be at the end of 2019?.

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

Yes, good question and one that we generally don't quote specific. As we know, the plasma market and as it's well documented, continues to expand at about 10% per year and we are growing at a faster rate than that. So that does imply we're picking up a little bit of market share but we don't forecast a specific full year perceptible end..

Operator

Our next question today is coming from William Gibson from Roth Capital Partners. Your line is now live. .

William Gibson

Mark, you mentioned introducing a premier card I believe this quarter.

What's different about that versus what you already have?.

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

Basically, the cards that we currently offer in general are our general corporate spend cards. Typically, more of a distribution type cards what little bit different about the premier card is that it's more of a full service card account, debit account.

So will offer direct deposit and it will offer you remote deposit capture, offer you bill pay, offer several other features that are more in-line with traditionally what you would see out there under the net spend and green dot offerings. .

Operator

[Operator Instructions]. If there are no further questions at this time, I'd like to turn the floor back over to management for any further or closing comments..

Mark Newcomer Co-Founder, President, Chief Executive Officer & Chairman

Yes. So we really appreciate the opportunity to convey a very strong quarter of results. We're very much focused on execution and growing the top line and delivering on what we've guided or better. We thank you for listening. .

Mark Attinger

Thanks, everyone. Appreciate it. .

Operator

Thank you. That does conclude today's teleconference. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today..

ALL TRANSCRIPTS
2024 Q-3 Q-2 Q-1
2023 Q-4 Q-3 Q-2 Q-1
2022 Q-4 Q-3 Q-2 Q-1
2021 Q-4 Q-3 Q-2 Q-1
2020 Q-4 Q-3 Q-2 Q-1
2019 Q-4 Q-3 Q-2 Q-1
2018 Q-4